National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Indacterol/mometasone furoate (Atectura®) is indicated as maintenance treatment of asthma in adults and adolescents 12 years and older not adequately controlled with inhaled corticosteroids and inhaled short acting β2 agonists.

 

NCPE Assessment Process Complete
Rapid review commissioned 13/05/2020
Rapid review completed 10/06/2020
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that Indacterol/mometasone furoate (Atectura®) be considered for reimbursement*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.